Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2C9, CYP2C19 genes and by the transporter ABCB1 gene can influence phenytoin (PTH) plasma levels and toxicity. The patient reported here is a 2-year-old girl with a medical history of cryptogenic (probably symptomatic) epilepsy, who had her first focal seizure with secondary generalization at 13 months of age. She initially received oral valproate treatment and three months later, she was prescribed an oral oxcarbazepine treatment. At 20 months of age, she was admitted to the Emergency Department because of generalized convulsive Status Epilepticus needing to be immediately treated with rectal diazepam (0.5 mg kg À1 ), intravenous diazepam (0.3 mg kg À1 ), and intravenous phenytoin with an initial-loading dose of 15 mg kg À1 . However, two hours after the initial-loading dose of PTH, the patient developed dizziness, nystagmus, ataxia and excessive sedation. Other potential causes of PTH toxicity were excluded such as drug interactions, decreased albumin or lab error. Therefore, to explain the neurological toxicity, PTH plasma levels and CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms were analyzed. Initial plasma PTH levels were higher than expected (69 mg l À1 ; normal range: 10--20 mg l À1 ), and the patient was homozygous for the CYP2C9*2 allele, heterozygous for the CYP2C19*4 allele and homozygous for the 3435C and 1236C ABCB1 alleles. Present findings support the previously established relationship between CYP2C9 and CYP2C19 genetic polymorphisms and the increased risk to develop PTH toxicity owing to high plasma concentrations. Nevertheless, although the association of these genes with PTH-induced adverse effects has been well-documented in adult populations, this is the first report examining the influence of these genetic polymorphisms on PTH plasma levels and toxicity in a pediatric patient.
INTRODUCTION
Phenytoin (PTH) is an antiepileptic drug metabolized by cytochrome P450 polymorphic enzymes CYP2C9 (90%) and CYP2C19 (10%). 1, 2 Individuals carrying at least one of the most common CYP2C9-reduced function alleles CYP2C9*2 or CYP2C9*3 (with a frequency of 16% and 10%, respectively, in the Spanish population), 3 will need a lower (30 to 40%) PTH dose to achieve therapeutic serum concentrations than those homozygous for CYP2C9*1. 4 Similarly, several CYP2C19-reduced null function allelic variants (*2, *3, *4) may cause a poor metabolizer phenotype, or the CYP2C19*17 with increased activity may cause an ultrarapid metabolizer phenotype. 2, 5 Population pharmacogenetic studies have shown that both CYP2C genes have an important role in the PTH pharmacokinetic variability. Therefore, careful monitoring is suggested for those individuals carrying CYP2C9-or CYP2C19-reduced or -null function alleles, who are expected to present increased PTH blood levels, particularly if taking high PTH doses. 6, 7 Additionally, PTH pharmacokinetic variability is dependent on the activity of p-glycoprotein, encoded by the human multi-drug resistance (MDR1) or ABCB1 gene.
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polymorphisms have been associated with differences in PTH transport as well as with drug-refractory epilepsy. 9, 10 In sum, pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2C9, CYP2C19 and by the ABCB1 transporter gene can influence PTH plasma levels and toxicity. 10--18 Nevertheless, although this association has been well-documented in adult populations, this is to our knowledge the first report examining the influence of these genetic polymorphisms on PTH plasma levels and toxicity in a pediatric patient.
MATERIALS AND METHODS
The patient reported here is a 2-year-old girl with a medical history of cryptogenic or probably symptomatic epilepsy. She was the first daughter, born to nonconsanguineous and healthy parents, with no family history of febrile seizures or epilepsy. Prenatal and perinatal histories were both uneventful. Initial developmental milestones were normal. She walked unaided at the age of 12 months.
At the age of 13 months, she had a first focal seizure with secondary generalization. Neurological examination and brain magnetic resonance imaging (MRI) results were normal, but she showed electroencephalography (EEG) spike-waves paroxysms in the temporal region of the left hemisphere and spike-waves in the occipito-parietal region of right hemisphere during normal waking hours. She initially received treatment with oral valproate achieving partial control of her seizures. Later at the age of 16 months, she was prescribed a treatment with oral oxcarbazepine achieving an adequate control of seizures.
At the age of 20 months, she was admitted to the emergency department because of generalized convulsive status epilepticus (SE) needing rectal diazepam (0.5 mg kg À1 ), intravenous diazepam (0.3 mg kg À1 ) and intravenous PTH with an initial-loading dose of 15 mg kg À1 , which is usually followed 18--24 h after a maintenance dose of 5 mg kg À1 per day. The convulsive status epilepticus with generalized tonic--clonic seizures lasted a total time of 30 min and stopped 15 min after the loading PTH dose was infused. The infusion rate of PTH in the patient was 1 mg Kg À1 min À1 . Two hours after the initial-loading intravenous PTH dosage was given, the patient was found to have dizziness, nystagmus (lateral and vertical), ataxia and excessive sedation. No further PTH was given after the infusion, when oxcarbazepine was restarted (30 mg kg À1 per day), and she has been seizure-free. The toxic symptoms disappeared at about 122 h after the onset of PTH infusion. The parents denied any toxic intake and reported no previous history of cranial trauma or infectious disease. Laboratory tests including hemogram, blood gasometry, serum electrolytes, renal function, liver enzymes, blood ammonia and lactate, blood and urine cultures and toxicology screen in urine were all normal. Additionally, brain magnetic resonance imaging and video-electroencephalography-polygraphic sleep recording did not show any abnormalities, and background activity during awake and sleep time was normal. Therefore, PTH toxicity was suspected and PTH plasma levels were determined.
In order to examine whether CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms might explain the above-mentioned PTH-induced neurological toxicity, pharmacogenetic analysis was applied.
Blood sample was collected in an EDTA tube, and DNA was extracted using the QIAamp DNA blood kit (QIAGEN, Hilden, Germany). Genotyping was performed for CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), CYP2C19*4 (rs28399504), and ABCB1 1236C4T (rs1128503) and 3435C4T (rs1045642) on a 7300 real-time PCR system (Applied Biosystems, Foster City, CA, USA). The sample was genotyped according to the manufacturer-suggested protocol for TaqMan s Drug Metabolism Genotyping Assays (Applied Biosystems). Signed informed consent was obtained from the parents for genotyping analyses. Plasma concentrations of PHT were analysed by HPLC method with photodiode-array detection as described by Liu et al.
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RESULTS
The initial PTH plasma level (2 h after dosing) was higher than normal (69 mg l À1 ; normal range between 10 and 20 mg l
À1
). As previously explained when PTH was stopped, the acute toxicity symptoms subsided following the decay in PTH plasma concentrations (Figure 1 ; on day 3, 54 mg l À1 ; on day 5, 30.8 mg l À1 ; on day 7, 15.5 mg l À1 ). Other causes related to toxic PTH concentration such as decreased albumin or lab error were excluded.
Pharmacogenetic analyses for the genes involved in PTH pharmacokinetics revealed that the patient was homozygous for the CYP2C9*2 allele, heterozygous for the CYP2C19*4 allele, homozygous for the 3435C and 1236C ABCB1 alleles. DISCUSSION PTH toxicity often occurs in patients who have predisposing factors for toxicity, such as malnourishment, chronic renal failure, hepatic dysfunction and inhibition of PTH metabolism by other drugs. However, even in the absence of these predisposing factors, patients carrying genetic mutations may also develop PTH toxicity. This is the first report examining the influence of genetic polymorphisms on PTH plasma levels and toxicity in a pediatric patient.
Present results support the previously established relationship between CYP2C9*2/*2 and CYP2C19*1/*4 genotypes and the increased risk to develop PTH toxicity due to high plasma concentrations. 20 Additionally, the patient was a carrier of ABCB1 3435C/C and 1236C/C genotypes, which have been associated with increased p-glycoprotein activity. 10, 21 In a previous study, it was found that the high p-glycoprotein expressing ABCB1 3435C allele was significantly overrepresented in volunteers with low PTH levels and might be therefore predictive of subtherapeutic plasma levels, 11 therefore, these polymorphisms did not explain the high plasma levels of PTH of this case. In addition, new studies are needed to evaluate the potential influence of these and other variant alleles on the risk of PTH intoxication.
Furthermore, in a study including 40 children (aged 8--33 months), the apparent Vmax and Km for PTH was estimated to be 20.4 mg kg À1 per day (0.85 mg kg À1 per h) and 7.5 mg l À1 , respectively. 22 According to the integrated Michaelis--Menten equation, 23 the PHT half-life of the patient would be 46.7 h from 69--34.5 mg l À1 , However, this study did not consider the genotype of patients. Therefore, if this value is compared with that observed in the present clinical case (112 h from 69--34.5 mg l
; Figure 1 ), the PHT half-life is much higher in the clinical case than in the general pediatric patients (112 vs 46.7 h), which could be explained by the influence of CYP2C9 and CYP2C19 genetic polymorphisms.
On the other hand, we cannot rule out the potential influence of oxcarbamacepine on the increase of PHT plasma levels, 24 although this influence has not been shown so potent to elevate the PTH concentrations, because oxcarbazepine has a low susceptibility to inhibit or induce oxidative enzymes. 25 In order to prevent adverse events, it might be wise to routinely perform the CYP2C9 and CYP2C19 genotype analyses in all epileptic patients before any signs of toxicity and include the genotyping data in their records together with a recommendation of a genotype-based dosing strategy, according to the existing knowledge of evidence.
In conclusion, the present findings support, in a pediatric patient, the previously established relationship between CYP2C9 and CYP2C19 genotypes, and the increased risk to develop PTH toxicity due to high plasma concentrations.
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